Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Collplant Holdings ( (CLGN) ) has shared an update.
On February 23, 2026, Israel-based CollPlant announced BioFlex, a ready-to-print rhCollagen-based kit tailored for Digital Light Processing 3D bioprinting systems. The launch targets biopharma companies and academic institutions seeking animal-free bioinks that offer superior biofunctionality, reproducibility, and tissue-mimetic performance.
BioFlex combines the company’s Collink.3D 50 biodegradable polymer with proprietary photoactive agents and standardized guidelines to streamline bioink formulation. The solution is designed to shorten development cycles and enable precise tuning of mechanical properties such as tensile strength, elasticity, and structural integrity.
By eliminating extensive component screening, the kit aims to reduce cost and complexity for users building advanced tissue models for drug discovery, tissue engineering, and potential organ applications. The move further expands CollPlant’s rhCollagen bioink platform and reinforces its positioning in the fast-growing 3D bioprinting and regenerative medicine markets.
CollPlant highlighted that constructs produced with BioFlex exhibit improved mechanical consistency and safety, supporting a more reliable translation from lab concepts to functional tissue constructs. The product is intended for use across academic labs and industrial R&D environments, strengthening the company’s role as a key technology supplier in next-generation bioprinting workflows.
The most recent analyst rating on (CLGN) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and a shrinking equity base despite some TTM revenue and gross margin improvement. Technicals provide partial support with a stronger short-term trend, but longer-term trend and momentum are mixed. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company specializing in 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on proprietary plant-derived recombinant human collagen (rhCollagen) and target tissue repair, aesthetics, and organ manufacturing, including a dermal and soft tissue filler partnership with Allergan, an AbbVie company.
Average Trading Volume: 72,869
Technical Sentiment Signal: Sell
Current Market Cap: $8.93M
Learn more about CLGN stock on TipRanks’ Stock Analysis page.